Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justine Decroocq

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Cancers|August 26, 2023
Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM)Marion Detroit, Mathis Collier, Nathanaël Beeker, et al.
Cell Reports|January 23, 2020
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone MarrowEtienne Paubelle, Florence Zylbersztejn, Thiago Trovati Maciel, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Science Advances|November 25, 2015
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemiaAlexa S Green, Thiago T Maciel, Marie-Anne Hospital, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
American Journal of Hematology|December 12, 2017
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie CellulaireJustine Decroocq, Raphaël Itzykson, Stéphane Vigouroux, et al.
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancers|August 26, 2023
Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM)Marion Detroit, Mathis Collier, Nathanaël Beeker, et al.
Cell Reports|January 23, 2020
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone MarrowEtienne Paubelle, Florence Zylbersztejn, Thiago Trovati Maciel, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Blood Cancer Journal|April 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsChristophe Willekens, Alexandre Bazinet, Samy Chraibi, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Science Advances|November 25, 2015
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemiaAlexa S Green, Thiago T Maciel, Marie-Anne Hospital, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
American Journal of Hematology|December 12, 2017
Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie CellulaireJustine Decroocq, Raphaël Itzykson, Stéphane Vigouroux, et al.
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.
Pageof 5